Orion Capital Management LLC Sells 100 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Orion Capital Management LLC trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,240 shares of the biopharmaceutical company’s stock after selling 100 shares during the period. Orion Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $1,057,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Brighton Jones LLC bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $243,000. GAMMA Investing LLC increased its holdings in Alnylam Pharmaceuticals by 14.3% during the first quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 77 shares during the last quarter. Bessemer Group Inc. raised its position in Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 69 shares during the period. Robeco Institutional Asset Management B.V. boosted its stake in shares of Alnylam Pharmaceuticals by 3.5% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 103,481 shares of the biopharmaceutical company’s stock worth $27,942,000 after acquiring an additional 3,487 shares during the last quarter. Finally, Sequoia Financial Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 3.0% during the 1st quarter. Sequoia Financial Advisors LLC now owns 3,395 shares of the biopharmaceutical company’s stock valued at $917,000 after acquiring an additional 99 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 8,924 shares of the stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the completion of the transaction, the chief executive officer directly owned 65,409 shares of the company’s stock, valued at approximately $29,568,138.45. This represents a 12.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Tolga Tanguler sold 1,405 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $635,130.25. Following the completion of the sale, the executive vice president directly owned 27,438 shares in the company, valued at approximately $12,403,347.90. The trade was a 4.87% decrease in their position. The disclosure for this sale can be found here. Insiders sold 98,144 shares of company stock valued at $44,160,261 in the last ninety days. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $463.43 on Friday. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The company’s fifty day moving average price is $459.27 and its 200-day moving average price is $360.97. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The company has a market capitalization of $60.75 billion, a PE ratio of -187.62 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million during the quarter, compared to analysts’ expectations of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. Alnylam Pharmaceuticals’s quarterly revenue was up 17.3% on a year-over-year basis. During the same period last year, the company posted ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ALNY has been the topic of several analyst reports. Barclays lifted their target price on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Citigroup lifted their price objective on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Stifel Nicolaus boosted their price objective on Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the company a “buy” rating in a research note on Monday, October 6th. Scotiabank raised their target price on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a “sector outperform” rating in a research note on Friday, August 1st. Finally, Morgan Stanley upped their price target on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a research report on Monday, October 6th. Twenty-three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $466.92.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.